Navigation Links
Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention
Date:6/16/2008

PRINCETON, N.J., June 16 /PRNewswire/ -- Celator Pharmaceuticals today announced that John Bennett, head of business development, is scheduled to present at the BIO Business Forum during the Biotechnology Industry Organization (BIO) International Convention in San Diego. Mr. Bennett will provide a corporate overview and an update on Celator's clinical development programs. The presentation will be held on Wednesday, June 18, 2008 at 3:30 PDT in Room 3 of the San Diego Convention Center.

About Celator

Celator Pharmaceuticals, Inc., is a privately held pharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex(TM), the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on identifying a fixed, synergistic ratio of the drugs pre-clinically, incorporating that ratio in a drug delivery vehicle and maintaining the ratio in patients. The company pipeline includes: CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in a Phase 2 trial in patients with colorectal cancer; CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in a Phase 1 trial in patients with leukemia; CPX 571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at http://www.celatorpharma.com.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
2. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
3. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
4. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
5. GlaxoSmithKline and Mpex Pharmaceuticals Form Alliance to Develop Novel Efflux Pump Inhibitors for Use Against Serious Gram-Negative Infections
6. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
7. Jazz Pharmaceuticals Files Form S-3 Registration Statements
8. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
9. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
10. The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
11. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... ... January 11, 2017 , ... For many fledging ... navigating the challenges young businesses face. With the second installment of Quorum’s newest ... of Geoff DiMasi, Founder and Principal of interactive design agency, P’unk Ave. ...
(Date:1/11/2017)... ... 11, 2017 , ... Back pain relief technology is now available without a ... positive back pain relief for WAR members. , This spinal restoration platform boasts utilization ... changing for millions suffering from chronic back pain. , What A Relief ...
(Date:1/11/2017)... England , PITTSBURGH and BENGALURU, ... -- Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE ... Food and Drug Administration (FDA) has accepted Mylan,s biologics ... for filing through the 351(k) pathway. This product is ... to treat certain HER2-positive breast cancers. The anticipated FDA ...
(Date:1/11/2017)... 11, 2017  GenVec, Inc. (NASDAQ: ... today that its chief scientific officer, Douglas ...  "AdenoVerse™ platform for translational development of innovative gene ... the upcoming Phacilitate Cell & Gene Therapy World ... Florida.  Dr. Brough,s presentation will highlight the utility ...
Breaking Biology Technology:
(Date:1/12/2017)... , January 12, 2017 A new report by Allied ... that the global biometric technology market is expected to generate revenue of $10.72 billion ... Continue Reading ... Allied Market Research ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) ...
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol ... Capital Group, Inc., has been named to the elite "Forbes 30 ...  was one of 600 people in 20 fields nationwide to be ... of the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers ...
(Date:1/6/2017)... BOULDER, Colo. , Jan. 5, 2017 /PRNewswire/ ... join the "Digital Life Alliance" established by iCarbonX, ... in 2015 to build a "Global Digital Health ... based on a combination of individual,s biological, behavioral ... Under the agreement between the companies, SomaLogic will ...
Breaking Biology News(10 mins):